Mark Olfson, MD, MPH

Clozapine and Blood Monitoring—Is Less Better?

July 18, 2017

In 2015, the FDA removed WBC monitoring altogether and reduced the threshold for ANCs before interruption of clozapine treatment was required. The current study looks at almost 250 clozapine-treated...

Mark Olfson, Christoph U. Correll, Ryan S. Sultan, et al

Original Research

Antipsychotic Medications in Adult Depression

July 5, 2017

Antipsychotic medications are increasingly prescribed to treat depression. But is this use always warranted? Read the article by Gerhard and colleagues to learn how often antipsychotics are prescribed in...

Mark Olfson, Christoph U. Correll, Tobias Gerhard, et al

Article

Mood Disorders and Antipsychotic Treatment in Youth

March 29, 2017

The increasing overlap of mood disorders and antipsychotic use in youth is a growing area of concern. This meta-analysis examined the current findings on the frequency of mood disorders...

Mark Olfson, Christoph U. Correll, Tobias Gerhard, et al

Original Research

Generalizability in Clinical Trials of Substance Abuse

January 25, 2017

If clinical trials by design exclude as many as 85% of individuals with a target disorder, how can these studies be representative of the clinical population? Discover in this...

Carlos Blanco, Mark Olfson, Edward V. Nunes, et al

Original Research

Generalizability of Neuroimaging Studies in 5 Common Psychiatric Disorders Based on the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

December 28, 2016

Carlos Blanco, Mark Olfson, Silvia Franco, et al

Supplement Article

Injectable Antipsychotics in Schizophrenia

September 30, 2016

Read the recommendations of experts on the use of long-acting injectable antipsychotic medications in patients with schizophrenia.

Leslie Citrome, Mark Olfson, John M. Kane, et al

Article

Antipsychotic Treatment of Adults in the United States

October 21, 2015

Mark Olfson, Marissa King, Michael Schoenbaum

InfoPack

Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes

August 26, 2014

Mark Olfson, John M. Kane, Christoph U. Correll, et al

Original Research

National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression

May 15, 2014

Mark Olfson, Christoph U. Correll, Tobias Gerhard, et al

Original Research

Trends in Office-Based Mental Health Care Provided by Psychiatrists and Primary Care Physicians

March 15, 2014

Carlos Blanco, Mark Olfson, Shuai Wang, et al

Original Research

National Trends in Long-Term Use of Antidepressant Medications: Results From the US National Health and Nutrition Examination Survey

December 10, 2013

Mark Olfson, Ramin Mojtabai

Article

Probability and Predictors of First Treatment Contact for Anxiety Disorders in the United States: Analysis of Data From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

November 15, 2013

Carlos Blanco, Mark Olfson, Shuai Wang, et al

Clozapine and Blood Monitoring—Is Less Better?

Antipsychotic Medications in Adult Depression

Mood Disorders and Antipsychotic Treatment in Youth

Generalizability in Clinical Trials of Substance Abuse

Generalizability of Neuroimaging Studies in 5 Common Psychiatric Disorders Based on the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

Injectable Antipsychotics in Schizophrenia

Antipsychotic Treatment of Adults in the United States

Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes

National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression

Trends in Office-Based Mental Health Care Provided by Psychiatrists and Primary Care Physicians

National Trends in Long-Term Use of Antidepressant Medications: Results From the US National Health and Nutrition Examination Survey

Probability and Predictors of First Treatment Contact for Anxiety Disorders in the United States: Analysis of Data From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

ELSEWHERE:

FOLLOW US:

Mark Olfson, MD, MPH

Clozapine and Blood Monitoring—Is Less Better?

Antipsychotic Medications in Adult Depression

Mood Disorders and Antipsychotic Treatment in Youth

Generalizability in Clinical Trials of Substance Abuse

Generalizability of Neuroimaging Studies in 5 Common Psychiatric Disorders Based on the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

Injectable Antipsychotics in Schizophrenia

Antipsychotic Treatment of Adults in the United States

Clinical and Cost Implications of Treating Schizophrenia: Safety, Efficacy, Relapse Prevention, and Patient Outcomes

National Trends in Second-Generation Antipsychotic Augmentation for Nonpsychotic Depression

Trends in Office-Based Mental Health Care Provided by Psychiatrists and Primary Care Physicians

National Trends in Long-Term Use of Antidepressant Medications: Results From the US National Health and Nutrition Examination Survey

Probability and Predictors of First Treatment Contact for Anxiety Disorders in the United States: Analysis of Data From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC)

Consensus Report on XT Use in Practice

Subscribe to readmore articles

Subscribe to read
more articles